Browsing Tag
SCOPE
2 posts
Scancell Holdings (LSE:SCLP): Can a Nasdaq deal fund its pivotal melanoma trial?
Scancell has strong melanoma data, but Phase 3 still needs funding. A Nasdaq deal could reset LSE:SCLP, or leave investors facing dilution and deal risk.
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.